Downloads
Title
Source name
Date
Harnessing the GLP-1R medicine wave
As a promising treatment for T2D and obesity, based on key trial data, the GLP-1R therapy market looks set to produce major sales up to 2030.
European pharmaceutical Review
23 Aug 2024
First-of-a-kind trial holds promise for obesity and pre-diabetes treatment
The treatment may reduce the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or who are overweight.
European pharmaceutical Review
21 Aug 2024
Enhancing cell proliferation in bioproduction with non-invasive technology
The method has potential in both biomanufacturing and production of autologous cell therapies, the research suggests.
European pharmaceutical Review
21 Aug 2024
Genmab appoints new EVP and Chief Technology Officer
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
European pharmaceutical Review
19 Aug 2024